Government's Weird Enzyme Could Turbocharge Cancer Immune Attacks
Published Date: 10/2/2025
Notice
Summary
The National Cancer Institute has a cool new invention called Acyloxyacyl Hydrolase (AOAH) that could help fight cancer by boosting the immune system. This invention is ready for companies or researchers to license or team up on, speeding up the journey from lab to real-life treatments. If you’re in biotech or cancer research, now’s the time to jump in and make a difference!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Government AOAH Invention Open For Licensing
The National Cancer Institute (NCI) is offering a government-owned invention called Acyloxyacyl Hydrolase (AOAH) and related methods for licensing or collaboration so companies and researchers can commercialize cancer immunotherapy research. If you run or work for a biotech company or cancer research group, you can pursue a license or collaboration with NCI to develop this federally funded technology.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-11367 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting science projects. If you’re involved in cell biology, heart disease, mental health, or cancer research, these reviews could impact your funding timeline and opportunities.
2026-11357 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
2026-11018 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late June and early July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10813 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Previous / Next Documents
Previous: 2025-19375 — Government Owned Inventions Available for Licensing: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health has created new mouse models that help scientists study heart problems linked to the Casq2 gene. These special mice can turn certain genes off in a controlled way, speeding up research and drug development. Researchers and biotech companies can now license this technology to boost their work, with no immediate costs but big potential for future breakthroughs.
Next: 2025-19377 — Arms Sales Notification
The Department of Defense just announced new arms sales to other countries, sharing details everyone can see. This means some nations will get new military gear soon, with clear info on costs and timing. It’s all about keeping things open and making sure the right people get the right tools at the right time.